CO2021011295A2 - Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb - Google Patents
Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhbInfo
- Publication number
- CO2021011295A2 CO2021011295A2 CONC2021/0011295A CO2021011295A CO2021011295A2 CO 2021011295 A2 CO2021011295 A2 CO 2021011295A2 CO 2021011295 A CO2021011295 A CO 2021011295A CO 2021011295 A2 CO2021011295 A2 CO 2021011295A2
- Authority
- CO
- Colombia
- Prior art keywords
- hbv
- ring fused
- induced diseases
- pyrimidone derivatives
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente solicitud se refiere a compuestos de acuerdo con la fórmula (I), composiciones farmacéuticas que comprenden al menos uno de dichos compuestos, su uso como medicamento y su uso en el tratamiento de la infección crónica por el virus de la hepatitis B (VHB). La divulgación se refiere además a métodos para preparar compuestos de acuerdo con la fórmula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19162954 | 2019-03-14 | ||
PCT/EP2020/056884 WO2020182990A1 (en) | 2019-03-14 | 2020-03-13 | Fused ring pyrimidone derivatives for use in the treatment of hbv infection or of hbv-induced diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021011295A2 true CO2021011295A2 (es) | 2021-09-20 |
Family
ID=65817822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0011295A CO2021011295A2 (es) | 2019-03-14 | 2021-08-26 | Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb |
Country Status (23)
Country | Link |
---|---|
US (1) | US20230091047A1 (es) |
EP (1) | EP3938362A1 (es) |
JP (1) | JP2022524456A (es) |
KR (1) | KR20210139319A (es) |
CN (1) | CN113710667A (es) |
AR (1) | AR118358A1 (es) |
AU (1) | AU2020235270A1 (es) |
BR (1) | BR112021017415A2 (es) |
CA (1) | CA3132531A1 (es) |
CL (1) | CL2021002390A1 (es) |
CO (1) | CO2021011295A2 (es) |
CR (1) | CR20210482A (es) |
DO (1) | DOP2021000185A (es) |
EA (1) | EA202192512A1 (es) |
EC (1) | ECSP21067189A (es) |
IL (1) | IL286210A (es) |
JO (1) | JOP20210249A1 (es) |
MA (1) | MA55286A (es) |
MX (1) | MX2021011107A (es) |
PE (1) | PE20212325A1 (es) |
SG (1) | SG11202109575UA (es) |
TW (1) | TW202100524A (es) |
WO (1) | WO2020182990A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202227435A (zh) * | 2020-09-11 | 2022-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 用於治療hbv感染或hbv誘發的疾病之稠合環嘧啶酮衍生物 |
CN116724038A (zh) * | 2020-10-21 | 2023-09-08 | 安力高医药股份有限公司 | 双环化合物 |
WO2022266193A1 (en) * | 2021-06-18 | 2022-12-22 | Aligos Therapeutics, Inc. | Bicyclic compounds |
US20230374008A1 (en) * | 2022-04-20 | 2023-11-23 | Aligos Therapeutics, Inc. | Bicyclic compounds |
WO2023205653A1 (en) * | 2022-04-20 | 2023-10-26 | Aligos Therapeutics, Inc. | Bicyclic compounds |
WO2024015425A1 (en) | 2022-07-14 | 2024-01-18 | Fmc Corporation | Herbicidal benzoxazines |
US20240150351A1 (en) * | 2022-09-30 | 2024-05-09 | Aligos Therapeutics, Inc. | Bicyclic compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2078719A4 (en) | 2006-09-28 | 2009-11-11 | Dainippon Sumitomo Pharma Co | COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION |
JP2010524940A (ja) * | 2007-04-20 | 2010-07-22 | シェーリング コーポレイション | ピリミジノン誘導体およびそれらの使用方法 |
CN101854597B (zh) | 2009-04-03 | 2015-06-03 | 中兴通讯股份有限公司 | 大消息模式融合ip消息传输方法及系统 |
WO2011111880A1 (ko) * | 2010-03-08 | 2011-09-15 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
JP2012126698A (ja) * | 2010-12-17 | 2012-07-05 | Tsutomu Takeuchi | テトラヒドロピリドピリミジン誘導体を有効成分とするbaffの結合阻害剤 |
JP6713465B2 (ja) * | 2014-12-30 | 2020-06-24 | ノヴィラ・セラピューティクス・インコーポレイテッド | B型肝炎感染症治療のための誘導体及び方法 |
CN110088104B (zh) * | 2016-11-03 | 2022-04-12 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的四氢吡啶并嘧啶化合物 |
-
2020
- 2020-03-13 TW TW109108504A patent/TW202100524A/zh unknown
- 2020-03-13 EP EP20710938.0A patent/EP3938362A1/en active Pending
- 2020-03-13 JP JP2021554985A patent/JP2022524456A/ja not_active Withdrawn
- 2020-03-13 WO PCT/EP2020/056884 patent/WO2020182990A1/en active Application Filing
- 2020-03-13 CR CR20210482A patent/CR20210482A/es unknown
- 2020-03-13 MA MA055286A patent/MA55286A/fr unknown
- 2020-03-13 KR KR1020217032292A patent/KR20210139319A/ko unknown
- 2020-03-13 BR BR112021017415A patent/BR112021017415A2/pt unknown
- 2020-03-13 MX MX2021011107A patent/MX2021011107A/es unknown
- 2020-03-13 AU AU2020235270A patent/AU2020235270A1/en not_active Abandoned
- 2020-03-13 US US17/438,767 patent/US20230091047A1/en active Pending
- 2020-03-13 CA CA3132531A patent/CA3132531A1/en active Pending
- 2020-03-13 JO JOP/2021/0249A patent/JOP20210249A1/ar unknown
- 2020-03-13 EA EA202192512A patent/EA202192512A1/ru unknown
- 2020-03-13 SG SG11202109575UA patent/SG11202109575UA/en unknown
- 2020-03-13 AR ARP200100713A patent/AR118358A1/es unknown
- 2020-03-13 PE PE2021001481A patent/PE20212325A1/es unknown
- 2020-03-13 CN CN202080020919.0A patent/CN113710667A/zh active Pending
-
2021
- 2021-08-26 CO CONC2021/0011295A patent/CO2021011295A2/es unknown
- 2021-09-09 IL IL286210A patent/IL286210A/en unknown
- 2021-09-09 DO DO2021000185A patent/DOP2021000185A/es unknown
- 2021-09-10 EC ECSENADI202167189A patent/ECSP21067189A/es unknown
- 2021-09-13 CL CL2021002390A patent/CL2021002390A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CL2021002390A1 (es) | 2022-04-22 |
EP3938362A1 (en) | 2022-01-19 |
SG11202109575UA (en) | 2021-09-29 |
CN113710667A (zh) | 2021-11-26 |
AU2020235270A1 (en) | 2021-08-12 |
ECSP21067189A (es) | 2021-11-18 |
JP2022524456A (ja) | 2022-05-02 |
IL286210A (en) | 2021-10-31 |
CR20210482A (es) | 2021-11-09 |
JOP20210249A1 (ar) | 2023-01-30 |
CA3132531A1 (en) | 2020-09-17 |
DOP2021000185A (es) | 2022-01-16 |
MA55286A (fr) | 2022-01-19 |
PE20212325A1 (es) | 2021-12-14 |
AR118358A1 (es) | 2021-09-29 |
US20230091047A1 (en) | 2023-03-23 |
BR112021017415A2 (pt) | 2022-02-01 |
TW202100524A (zh) | 2021-01-01 |
KR20210139319A (ko) | 2021-11-22 |
WO2020182990A1 (en) | 2020-09-17 |
EA202192512A1 (ru) | 2022-02-16 |
MX2021011107A (es) | 2022-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021011295A2 (es) | Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb | |
BR112018075465A2 (pt) | agentes antivirais de hepatite b | |
CL2018002528A1 (es) | Agentes anti virales de la hepatitis b. | |
EA201891876A1 (ru) | Тетрациклические пиридоновые соединения в качестве противовирусных средств | |
CL2018002549A1 (es) | Eliminación del virus de la hepatitis b con agentes antivirales | |
UY38483A (es) | Heterociclos funcionalizados como agentes antivirales | |
UY37741A (es) | Derivados de indolina sustituidos como inhibidores de la replicación del virus del dengue | |
CO2019010295A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
BR112017011941A2 (pt) | compostos 5-amino-6h-tiazol [4,5-d] pirimidina-2,7-diona substituídos 3 para o tratamento e profilaxia de infecção viral | |
BR112015024552A2 (pt) | compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções | |
BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
CO2019010292A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
CO2019012035A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
BR112017020837A2 (pt) | compostos de carbamoilpiridona policíclicos e seu uso farmacêutico | |
CL2015001971A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas. | |
BR112014019584A8 (pt) | Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c | |
UY38383A (es) | Heterociclos funcionalizados como agentes antivirales | |
JO3281B1 (ar) | مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي | |
MX2021010145A (es) | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. | |
BR112014015582A8 (pt) | compostos antivirais | |
BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? | |
CL2017001161A1 (es) | Composiciones farmacéuticas de acción prolongada para la hepatitis c | |
CL2017001160A1 (es) | Combinación de composiciones de acción prolongada y métodos para la hepatitis c | |
EA201692514A1 (ru) | Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением |